Form 8-K Aquestive Therapeutics, For: Nov 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Aquestive Therapeutics (AQST) PT Raised to $24 at RBC Capital
November 7, 2018 7:09 AM ESTRBC Capital analyst Randall Stanicky raised the price target on Aquestive Therapeutics (NASDAQ: AQST) to $24.00 (from $23.00) while maintaining an Outperform rating following results.
Stanicky said pending Sympazan launch set to pave the way for lead product Libervant next year.
... More